Efficacy of Infliximab Biosimilars in Patients With Crohn's Disease

The Lancet - United Kingdom
doi 10.1016/s0140-6736(17)32459-5
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Elsevier BV

Related search

Efficacy of Adalimumab in Patients With Crohn's Disease and Failure to Infliximab Therapy: A Clinical Series

Revista Espanola de Enfermedades Digestivas
MedicineGastroenterology
2011English

Pgi9 - Systematic Review and Meta-Analysis of the Efficacy of Infliximab Biosimilars in Inflammatory Bowel Disease Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Higher Infliximab Trough Levels Are Associated With Perianal Fistula Healing in Patients With Crohn's Disease

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

New England Journal of Medicine
Medicine
2010English

Clinical Efficacy of Adalimumab Versus Infliximab and the Factors Associated With Recurrence or Aggravation During Treatment of Anal Fistulas in Crohn's Disease

Intestinal Research
Gastroenterology
2017English

Platelet Count in Patients With Crohn's Disease

BMJ
1983English

Infliximab and Adalimumab Drug Levels in Crohn's Disease: Contrasting Associations With Disease Activity and Influencing Factors

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Amyloidosis and Renal Disease in Patients With Crohn's Disease

2020English

Prm142 - Quantitative Benefit-Risk Modelling of Biosimilars: A Case Study of Infliximab in Crohn’s Disease.

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy